कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन के इंटरैक्शन

Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (एक्सेमेस्टेन लेबल, चेतावनियां और सावधानियां)

WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA • Women taking DUAVEE should not take additional estrogens [see Warnings and Precautions (5.1) ] • There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, बॉक्स्ड चेतावनी)

WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA • Women taking DUAVEE should not take additional estrogens [see Warnings and Precautions (5.1) ] • There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, बॉक्स्ड चेतावनी)

Estrogen Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacological action. (एनास्ट्रोज़ोल लेबल, दवाओं के इंटरैक्शन)

Primary forms of contraception include: tubal ligation, partner’s vasectomy, intrauterine devices, birth control pills, and injectable/implantable/insertable/topical hormonal birth control products. (एसिट्रेटिन लेबल, बॉक्स्ड चेतावनी)

WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA • Women taking DUAVEE should not take additional estrogens [see Warnings and Precautions (5.1) ] • There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, बॉक्स्ड चेतावनी)

WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA • Women taking DUAVEE should not take additional estrogens [see Warnings and Precautions (5.1) ] • There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, बॉक्स्ड चेतावनी)

WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA • Women taking DUAVEE should not take additional estrogens [see Warnings and Precautions (5.1) ] • There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, बॉक्स्ड चेतावनी)

WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA • Women taking DUAVEE should not take additional estrogens [see Warnings and Precautions (5.1) ] • There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, बॉक्स्ड चेतावनी)

WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA • Women taking DUAVEE should not take additional estrogens [see Warnings and Precautions (5.1) ] • There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, बॉक्स्ड चेतावनी)

Women taking estrogen-containing oral contraceptives may be at increased risk of becoming pregnant while on griseofulvin (see also PRECAUTIONS, Drug Interactions ) . (ग्रिसियोफुल्विन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Moderate or Weak CYP1A2 Inhibitors Concomitant use of Zanaflex with moderate or weak CYP1A2 inhibitors (e.g., zileuton, antiarrhythmics [amiodarone, mexiletine, propafenone, and verapamil], cimetidine, famotidine, oral contraceptives, acyclovir, and ticlopidine) should be avoided. (टिज़ानिडिन लेबल, दवाओं के इंटरैक्शन)

Concomitant use of combined hormonal contraceptives ( 4.1 ) (ट्रैनेक्सामिक एसिड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA • Women taking DUAVEE should not take additional estrogens [see Warnings and Precautions (5.1) ] • There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, बॉक्स्ड चेतावनी)

WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA • Women taking DUAVEE should not take additional estrogens [see Warnings and Precautions (5.1) ] • There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, बॉक्स्ड चेतावनी)

CONTRAINDICATIONS Progestin-only oral contraceptives (POPs) should not be used by women who currently have the following conditions: • Known or suspected pregnancy • Known or suspected carcinoma of the breast. (नॉरएथिस्टेरोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA • Women taking DUAVEE should not take additional estrogens [see Warnings and Precautions (5.1) ] • There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, बॉक्स्ड चेतावनी)

WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA • Women taking DUAVEE should not take additional estrogens [see Warnings and Precautions (5.1) ] • There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, बॉक्स्ड चेतावनी)

WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA • Women taking DUAVEE should not take additional estrogens [see Warnings and Precautions (5.1) ] • There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, बॉक्स्ड चेतावनी)

WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA • Women taking DUAVEE should not take additional estrogens [see Warnings and Precautions (5.1) ] • There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, बॉक्स्ड चेतावनी)

Coronary Heart Disease In women 50 to 59 years of age, the WHI estrogen plus progestin trial reported a relative risk for coronary heart disease (CHD) events (defined as nonfatal MI, silent MI, or CHD death) of 1.34 (95% CI, 0.82, 2.19) for CE/MPA compared placebo, with a risk difference of 5 per 10,000 WYs (23 versus 17). (प्रोजेस्टेरोन लेबल, चेतावनियां)

WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA • Women taking DUAVEE should not take additional estrogens [see Warnings and Precautions (5.1) ] • There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, बॉक्स्ड चेतावनी)

Hormonal contraceptives: Avoid concomitant use with LYSODREN. (माइटोटेन लेबल, दवाओं के इंटरैक्शन)

Sensitive CYP3A substrates including hormonal contraceptives: Avoid concomitant use with substrates that have narrow therapeutic index. (मिटापिवैट लेबल, दवाओं के इंटरैक्शन)

Hormonal contraceptives: Do not use with mifepristone ( 7.6 ). (मिफेप्रिस्टोन लेबल, दवाओं के इंटरैक्शन)

Concomitant Use with Systemic Estrogens : Not recommended. (रैलोक्सीफेन लेबल, चेतावनियां और सावधानियां)

WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA • Women taking DUAVEE should not take additional estrogens [see Warnings and Precautions (5.1) ] • There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, बॉक्स्ड चेतावनी)

John's Wort (CYP450 inducer; P-gp inducer) Significantly Reduced Contraindicated Oral Contraceptives containing ethinyl estradiol and norethindrone (CYP2C19 Inhibition) Increased Monitoring for adverse reactions and toxicity related to voriconazole is recommended for concomitant administration with oral contraceptives. (वोरिकोनाज़ोल लेबल, दवाओं के इंटरैक्शन)

सेंट जॉन्स वॉर्ट गर्भनिरोधक गोलियों का असर कम कर सकता है। (NCCIH, St. John's Wort)

Drugs Affecting Lipid Metabolism Estrogens, oral contraceptives, and clofibrate (and perhaps other lipid-lowering drugs) increase hepatic cholesterol secretion and encourage cholesterol gallstone formation and hence may counteract the effectiveness of URSO 250 and URSO Forte. (अर्सोडिऑक्सीकोलिक एसिड लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

…Glucose Lowering Effect of Insulin Aspart Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline),… (इंसुलिन एस्पार्ट लेबल, दवाओं के इंटरैक्शन)

…Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline),… (इंसुलिन ग्लार्जिन लेबल, दवाओं के इंटरैक्शन)

…Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline),… (इंसुलिन डेग्लुडेक लेबल, दवाओं के इंटरैक्शन)

…Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline),… (इंसुलिन डेटेमिर लेबल, दवाओं के इंटरैक्शन)

…Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline),… (इंसुलिन लिस्प्रो लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

• Oral Contraceptives: May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contraceptive ( 7.3 ). (एटोरवास्टेटिन लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Estrogen Estrogen containing oral contraceptives decrease theophylline clearance in a dose-dependent fashion. (एमिनोफाइलिन लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Amoxicillin may reduce the efficacy of oral contraceptives. (एमोक्सिसिलिन लेबल, दवाओं के इंटरैक्शन)

Amoxicillin and Clavulanate Potassium Extended Release Tablets may reduce efficacy of oral contraceptives. (एमोक्सिसिलिन और क्लैवुलैनेट लेबल, दवाओं के इंटरैक्शन)

Oral Contraceptives : May be less effective and increased breakthrough bleeding may occur. (एम्पीसिलिन लेबल, दवाओं के इंटरैक्शन)

• Oral Contraceptives: May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contraceptive ( 7.5 ). (एम्लोडिपिन और एटोरवास्टेटिन लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (एलेक्साकैफ्टर, टेज़ाकैफ्टर और आइवाकैफ्टर लेबल, दवाओं के इंटरैक्शन)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs and isoniazid Alogliptin Cytochrome (CYP) P450, CYP-Substrates or Inhibitors Clinical Impact: Insulin Secretagogues and Insulin Insulin and insulin secretagogues… (एलोग्लिप्टिन और मेटफॉर्मिन लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Hormonal Contraceptives: APTIOM may decrease the effectiveness of hormonal contraceptives. (एस्लिकार्बाज़ेपिन लेबल, दवाओं के इंटरैक्शन)

Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (ऑक्ट्रियोटाइड लेबल, दवाओं के इंटरैक्शन)

Oral Contraceptive: TRILEPTAL may decrease the effectiveness of hormonal contraceptives ( 7.3 ) (ऑक्सकार्बाज़ेपिन लेबल, दवाओं के इंटरैक्शन)

Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

John's Wort (Hypericum perforatum) preparations, phenobarbital, carbamazepine, and rifampin, may reduce plasma concentrations of some estrogens, possibly resulting in a decrease in therapeutic effects and/or changes in the uterine bleeding profile. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Drugs without Clinically Significant Interactions with Cabotegravir Based on drug interaction study results, the following drugs can be coadministered with cabotegravir without a dose adjustment: etravirine, midazolam, oral contraceptives containing levonorgestrel and ethinyl estradiol, rifabutin, and rilpivirine [see Clinical Pharmacology ( 12.3 )] . (कैबोटेग्राविर लेबल, दवाओं के इंटरैक्शन)

Drugs That Increase the Risk of Hypercalcemia Increase frequency of monitoring of calcium concentrations in patients taking concomitant Calcium Chloride Injection and other drugs that increase the risk of hypercalcemia (e.g., calcipotriene, estrogen, lithium, parathyroid hormone, teriparatide, thiazide diuretics, Vitamin A, and Vitamin D). (कैल्शियम क्लोराइड लेबल, दवाओं के इंटरैक्शन)

Plasma cholinesterase activity may be decreased by chronic administration of certain monoamine oxidase inhibitors, oral contraceptives, glucocorticoids, antimyasthenics (neostigmine), cyclophosphamide, and possibly thiotepa. (कोकेन लेबल, दवाओं के इंटरैक्शन)

Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (कोरियोगोनाडोट्रोपिन अल्फा लेबल, चेतावनियां)

Concomitant use with colesevelam hydrochloride may decrease the exposure of the following drugs: Drugs with a narrow therapeutic index (e.g., cyclosporine), phenytoin, thyroid hormone replacement therapy, warfarin, oral contraceptives containing ethinyl estradiol and norethindrone, olmesartan medoxomil, and sulfonylureas (glimepiride, glipizide, glyburide). (कोलेसेवेलम लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Cholestyramine for Oral Suspension USP may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic), or propranolol (basic), as well as tetracycline, penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis. (कोलेस्टिरामिन लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

Oral Contraceptives (Estrogen, Progestin) In 7 healthy females who were using single-ingredient progestin or combination estrogen-containing oral contraceptives, the pharmacokinetic parameters of a single 600 mg dose of quinine sulfate were not altered in comparison to those observed in 7 age-matched female control subjects not using oral contraceptives. (क्विनीन लेबल, दवाओं के इंटरैक्शन)

Oral Contraceptive Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg three times a day; N=13). (गैबापेंटिन लेबल, दवाओं के इंटरैक्शन)

Tumor Flare Phenomenon Initially, ZOLADEX, like other GnRH agonists, causes transient increases in serum levels of testosterone in men with prostate cancer, and estrogen in women with breast cancer. (गोसेरेलिन लेबल, चेतावनियां और सावधानियां)

…GLUCOTROL XL, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline),… (ग्लिपिज़ाइड लेबल, दवाओं के इंटरैक्शन)

…somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid. (ग्लिमेपिराइड लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (टिर्ज़ेपाटाइड लेबल, दवाओं के इंटरैक्शन)

Chronic increase in serum prolactin levels (although not evaluated in the tetrabenazine development program) has been associated with low levels of estrogen and increased risk of osteoporosis. (टेट्राबेनाज़िन लेबल, चेतावनियां और सावधानियां)

• Monitor thyroid function in women on thyroid replacement therapy ( 5.10 , 5.17 ) (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

Effect of AUBAGIO on Oral Contraceptives AUBAGIO may increase the systemic exposures of ethinylestradiol and levonorgestrel. (टेरिफ्लुनोमाइड लेबल, दवाओं के इंटरैक्शन)

Free hormone concentrations, such as testosterone and estradiol, may be decreased. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and… (टैक्रोलिमस लेबल, दवाओं के इंटरैक्शन)

Hypercalcemia in Patients with Metastatic Breast Cancer As with other additive hormonal therapy (estrogens and androgens), hypercalcemia has been reported in some breast cancer patients with bone metastases within a few weeks of starting treatment with tamoxifen. (टैमोक्सीफेन लेबल, चेतावनियां और सावधानियां)

Patients taking estrogen-containing or progestin-only contraceptives should be asked to report any change in their bleeding patterns. (टोपिरामेट लेबल, दवाओं के इंटरैक्शन)

Exercise caution when coadministering TOFIDENCE with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc. (टोसिलिज़ुमैब लेबल, दवाओं के इंटरैक्शन)

Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

Aspirin, carbapenem antibiotics, estrogen-containing hormonal contraceptives, methotrexate: Monitoring of valproate concentrations is recommended ( 7.1 ) (डाइवैल्प्रोएक्स (वैल्प्रोएट) लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

…budesonide, buspirone, conivaptan, cyclosporine, darifenacin, darunavir, dasatinib, dihydroergotamine, dronedarone, eletriptan, eplerenone, ergotamine, everolimus, felodipine, fentanyl, hormonal contraceptive agents, indinavir, fluticasone, lopinavir, lovastatin, lurasidone, maraviroc, midazolam, nisoldipine, pimozide, quetiapine, quinidine, saquinavir, sildenafil,… (डेफेरासिरोक्स लेबल, दवाओं के इंटरैक्शन)

Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

Free hormone concentrations, such as testosterone and estradiol, may be decreased. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

…following drugs can be coadministered with dolutegravir without a dose adjustment: atazanavir/ritonavir, darunavir/ritonavir, elbasvir/grazoprevir, methadone, midazolam, omeprazole, oral contraceptives containing norgestimate and ethinyl estradiol, prednisone, rifabutin, rilpivirine, sofosbuvir/velpatasvir, and tenofovir [see Clinical Pharmacology ( 12.3 )] . (डोलुटेग्राविर लेबल, दवाओं के इंटरैक्शन)

Chronic increase in serum prolactin levels (although not evaluated in the AUSTEDO XR, AUSTEDO, or tetrabenazine development programs) has been associated with low levels of estrogen and increased risk of osteoporosis. (ड्यूटेट्राबेनाज़िन लेबल, चेतावनियां और सावधानियां)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Risk factors for arterial vascular disease (for example, hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or VTE (for example, personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

Estrogen Estrogen containing oral contraceptives decrease theophylline clearance in a dose-dependent fashion. (थियोफाइलिन लेबल, दवाओं के इंटरैक्शन)

Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (निंटेडानिब लेबल, चेतावनियां और सावधानियां)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

…somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid. (पियोग्लिटाज़ोन और ग्लिमेपिराइड लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

• Monitor thyroid function in women on thyroid replacement therapy ( 5.10 , 5.17 ) (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

Oral Contraceptives Clinical Impact Co-administration of multiple-dose phentermine and topiramate extended-release capsules 15 mg/92 mg once daily with a single dose of oral contraceptive containing 35 µg ethinyl estradiol (estrogen component) and 1 mg norethindrone (progestin component), in obese otherwise healthy volunteers, decreased the exposure of ethinyl… (फेंटरमिन और टोपिरामेट लेबल, दवाओं के इंटरैक्शन)

The metabolism of bazedoxifene may be increased by concomitant use of substances known to induce UGTs, such as rifampin, phenobarbital, carbamazepine, and phenytoin. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

John's Wort (Hypericum perforatum) preparations, phenobarbital, carbamazepine, and rifampin, may reduce plasma concentrations of some estrogens, possibly resulting in a decrease in therapeutic effects and/or changes in the uterine bleeding profile. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

John's Wort (Hypericum perforatum) preparations, phenobarbital, carbamazepine, and rifampin, may reduce plasma concentrations of some estrogens, possibly resulting in a decrease in therapeutic effects and/or changes in the uterine bleeding profile. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Effects of Felbatol ® on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 µg ethinyl estradiol and 75 µg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive… (फेल्बामेट लेबल, दवाओं के इंटरैक्शन)

Use of ultrasound monitoring of ovarian response and/or measurement of serum estradiol levels is important to minimize the risk of overstimulation [see Warnings and Precautions (5.8) ] . (फॉलिट्रोपिन लेबल, चेतावनियां और सावधानियां)

…omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine, sulfamethoxazole-trimethoprim Other Acute alcohol intake, amiodarone, chloramphenicol, chlordiazepoxide, disulfiram, estrogen, fluvastatin, isoniazid, methylphenidate, phenothiazines, salicylates, ticlopidine, tolbutamide, trazodone, warfarin Drugs that may decrease phenytoin serum levels Antineoplastic… (फॉस्फेनिटोइन लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Weak CYP3A4 Inhibitors Examples Oral contraceptives, cimetidine, fluoxetine, ginkgo, ranitidine Clinical Implications The concomitant use of ADDYI with multiple weak CYP3A4 inhibitors may increase the risk of adverse reactions. (फ्लिबैनसेरिन लेबल, दवाओं के इंटरैक्शन)

Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Free hormone concentrations, such as testosterone and estradiol, may be decreased. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

Free hormone concentrations, such as testosterone and estradiol, may be decreased. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (बिस्मथ सबसाइट्रेट, मेट्रोनिडाज़ोल और टेट्रासाइक्लिन लेबल, दवाओं के इंटरैक्शन)

Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

Hormonal contraceptives: TRACLEER use decreases contraceptive exposure and reduces effectiveness ( 7.2 ). (बोसेंटन लेबल, दवाओं के इंटरैक्शन)

Mycophenolate mofetil may reduce effectiveness of oral contraceptives. (माइकोफेनोलेट लेबल, दवाओं के इंटरैक्शन)

Free hormone concentrations, such as testosterone and estradiol, may be decreased. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

• Women taking DUAVEE should not take progestins, additional estrogens or additional estrogen agonist/antagonists ( 5.1 ) (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

• Women taking DUAVEE should not take progestins, additional estrogens or additional estrogen agonist/antagonists ( 5.1 ) (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

• Monitor thyroid function in women on thyroid replacement therapy ( 5.10 , 5.17 ) (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

Advise women to follow the instructions on the initiation or resumption of hormonal contraceptives after ella intake [see Dosage and Administration(2.2) ]. (यूलिप्रिस्टल लेबल, चेतावनियां और सावधानियां)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Hormonal Contraceptives PRIFTIN may reduce the effectiveness of hormonal contraceptives. (रिफापेंटिन लेबल, दवाओं के इंटरैक्शन)

John's Wort (Hypericum perforatum) preparations, phenobarbital, carbamazepine, and rifampin, may reduce plasma concentrations of some estrogens, possibly resulting in a decrease in therapeutic effects and/or changes in the uterine bleeding profile. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (रिलुज़ोल लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Estrogens Population pharmacokinetic analysis revealed that higher doses of estrogens (usually associated with hormone replacement therapy) reduced the clearance of ropinirole. (रोपिनिरोल लेबल, दवाओं के इंटरैक्शन)

Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (रोफ्लुमिलास्ट लेबल, दवाओं के इंटरैक्शन)

• Monitor thyroid function in women on thyroid replacement therapy ( 5.10 , 5.17 ) (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

ESAs and estrogens may further increase the risk of thrombosis and their use should be based on a benefit-risk decision in patients receiving REVLIMID [see Drug Interactions (7.2) ]. (लेनालिडोमाइड लेबल, चेतावनियां और सावधानियां)

Effect on Oral Contraceptives Teriflunomide may increase the systemic exposures of ethinylestradiol and levonorgestrel. (लेफ्लुनोमाइड लेबल, दवाओं के इंटरैक्शन)

• Monitor thyroid function in women on thyroid replacement therapy ( 5.10 , 5.17 ) (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

• Monitor thyroid function in women on thyroid replacement therapy ( 5.10 , 5.17 ) (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

• Women taking DUAVEE should not take progestins, additional estrogens or additional estrogen agonist/antagonists ( 5.1 ) (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

Concomitant Use with Estrogen-Containing Products, Including Oral Contraceptives Some estrogen-containing oral contraceptives have been shown to decrease serum concentrations of lamotrigine [see Clinical Pharmacology ( 12.3 )] . (लैमोट्रिजिन लेबल, चेतावनियां और सावधानियां)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Careful titration may then be considered based on LDL-C response and safety/tolerability to a maximum recommended dosage of 30 mg daily except when coadministered with oral contraceptives, in which case the maximum recommended lomitapide dosage is 40 mg daily [see Dosage and Administration (2.3) and Drug Interactions (7.2) ]. (लोमिटापाइड लेबल, चेतावनियां और सावधानियां)

Advise females of reproductive potential to use an effective non-hormonal method of contraception, since LORBRENA can render hormonal contraceptives ineffective, during treatment with LORBRENA and for at least 6 months after the final dose. (लोरलाटिनिब लेबल, चेतावनियां और सावधानियां)

…carbamazepine, phenobarbital, rifampin CYP1A2 acyclovir, allopurinol, caffeine, cimetidine, ciprofloxacin, disulfiram, enoxacin, famotidine, fluvoxamine, methoxsalen, mexiletine, norfloxacin, oral contraceptives, phenylpropanolamine, propafenone, propranolol, terbinafine, thiabendazole, ticlopidine, verapamil, zileuton montelukast, moricizine, omeprazole, phenobarbital,… (वारफेरिन लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Aspirin, carbapenem antibiotics, estrogen-containing hormonal contraceptives: Monitoring of valproate concentrations is recommended (7.1) (वैल्प्रोइक एसिड लेबल, दवाओं के इंटरैक्शन)

The neuromuscular blocking effect of succinylcholine may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase [see Warnings and Precautions (5.9) ]. (सक्सिनिलकोलिन लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Therefore, the administration of a bolus dose of BRIDION is considered to be equivalent to missing dose(s) of oral contraceptives containing an estrogen or progestogen. (सुगैमाडेक्स लेबल, दवाओं के इंटरैक्शन)

…contraceptives containing progestins other than levonorgestrel and norethindrone should use additional nonhormonal contraceptives (such as condoms) or use alternative contraceptives (e.g., a combined oral contraceptive containing ethinyl estradiol as the estrogen and levonorgestrel or norethindrone as the progestin, an intrauterine system) during JOURNAVX treatment and… (सुज़ेट्रिजिन लेबल, चेतावनियां और सावधानियां)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Oral Estrogen Clinical Impact: Oral estrogens may reduce the serum IGF-1 response to HUMATROPE. (सोमाट्रोपिन लेबल, दवाओं के इंटरैक्शन)

Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

• Large doses of salicylates, cortisone, adrenocorticotropic hormone (ACTH), estrogens or antihistamines may require larger amounts of hyaluronidase for equivalent dispersing effect ( 7.4 ) (हायल्यूरोनिडेज़ लेबल, दवाओं के इंटरैक्शन)

Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

Oral Contraceptives Isotretinoin Capsules did not result in clinically significant changes in the pharmacokinetics of norethindrone and ethinyl estradiol when used concomitantly with a norethindrone and ethinyl estradiol oral contraceptive [see Clinical Pharmacology ( 12.3 )]. (आइसोट्रेटिनोइन लेबल, दवाओं के इंटरैक्शन)

Inducers of CYP3A4, such as St. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid. (एकार्बोज़ लेबल, दवाओं के इंटरैक्शन)

Inducers of CYP3A4, such as St. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (एम्पाग्लिफ्लोज़िन और मेटफॉर्मिन लेबल, दवाओं के इंटरैक्शन)

Drugs that may cause hypercalcemia: Vitamin D, vitamin A, thiazide diuretics, estrogen, calcipotriene and teriparatide administration may cause hypercalcemia. (कैल्शियम ग्लूकोनेट लेबल, दवाओं के इंटरैक्शन)

Moderate or weak CYP1A2 inhibitors include oral contraceptives and caffeine. (क्लोज़ापिन लेबल, दवाओं के इंटरैक्शन)

Inducers of CYP3A4, such as St. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (ग्लिपिज़ाइड और मेटफॉर्मिन लेबल, सावधानियां)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (ग्लिबेनक्लामाइड लेबल, दवाओं के इंटरैक्शन)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (ग्लिबेनक्लामाइड और मेटफॉर्मिन लेबल, दवाओं के इंटरैक्शन)

Oral Contraceptives In vivo studies have revealed no effect of ziprasidone on the pharmacokinetics of estrogen or progesterone components. (ज़िप्रासिडोन लेबल, दवाओं के इंटरैक्शन)

There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, phenytoins, thiazide diuretics, and calcium channel blockers. (टर्बिनाफिन लेबल, दवाओं के इंटरैक्शन)

Oral Contraceptives Concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective. (टाइजेसाइक्लिन लेबल, दवाओं के इंटरैक्शन)

Concurrent use of tetracycline may render oral contraceptives less effective. (टेट्रासाइक्लिन लेबल, दवाओं के इंटरैक्शन)

Oral Contraceptives The effect of oral contraceptives on the pharmacokinetics of Dihydroergotamine Mesylate Injection, USP has not been studied. (डाइहाइड्रोएर्गोटामिन लेबल, दवाओं के इंटरैक्शन)

Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective. (डेमेक्लोसाइक्लिन लेबल, दवाओं के इंटरैक्शन)

These medications include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (डैपाग्लिफ्लोज़िन और मेटफॉर्मिन लेबल, दवाओं के इंटरैक्शन)

Concurrent use of tetracyclines, including doxycycline hyclate may render oral contraceptives less effective. (डॉक्सीसाइक्लिन लेबल, दवाओं के इंटरैक्शन)

Moderate and weak CYP3A4 inhibitors include alprozalam, ameprenavir, amiodarone, aprepitant, atazanavir, cimetidine, cyclosporine, diltiazem, erythromycin, fluconazole, fluoxetine, isoniazid, oral contraceptives, quinuprestin/dalfopristin, valproic acid, and verapamil. (निमोडिपिन लेबल, दवाओं के इंटरैक्शन)

Inducers of CYP3A4, such as St. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

…been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sjogren's efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. (पाइलोकार्पिन लेबल, दवाओं के इंटरैक्शन)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (पियोग्लिटाज़ोन और मेटफॉर्मिन लेबल, दवाओं के इंटरैक्शन)

Inducers of CYP3A4, such as St. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

No pharmacokinetic interactions were observed between LYRICA and carbamazepine, gabapentin, lamotrigine, oral contraceptive, phenobarbital, phenytoin, topiramate, and valproic acid. (प्रीगैबलिन लेबल, दवाओं के इंटरैक्शन)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (बेक्सारोटीन लेबल, दवाओं के इंटरैक्शन)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (मेटफॉर्मिन लेबल, दवाओं के इंटरैक्शन)

Inducers of CYP3A4, such as St. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Inducers of CYP3A4, such as St. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Hormone Therapy Concomitant use of Risedronate sodium delayed-release with estrogens and estrogen agonist/antagonists has not been studied. (रिसेड्रोनेट लेबल, दवाओं के इंटरैक्शन)

Hormonal contraceptives may be less effective with BANZEL; use additional non-hormonal forms of contraception ( 7.3 ) (रुफिनामाइड लेबल, दवाओं के इंटरैक्शन)

Atypical Antipsychotics (e.g., olanzapine and clozapine), Corticosteroids, Danazol, Diuretics, Estrogens, Glucagon, Isoniazid, Niacin, Oral Contraceptives, Phenothiazines, Progestogens (e.g., in oral contraceptives), Protease inhibitors, Somatropin, Sympathomimetic Agents (e.g., albuterol, epinephrine, terbutaline) and Thyroid Hormones. (रेगुलर इंसुलिन (ह्यूमन) लेबल, दवाओं के इंटरैक्शन)

Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and… (रेपाग्लिनाइड लेबल, दवाओं के इंटरैक्शन)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (लिनाग्लिप्टिन और मेटफॉर्मिन लेबल, दवाओं के इंटरैक्शन)

Potential pharmacokinetic interactions of or with levetiracetam were assessed in clinical pharmacokinetic studies (phenytoin, valproate, warfarin, digoxin, oral contraceptive, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients. (लेवेटिरासेटम लेबल, दवाओं के इंटरैक्शन)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (सिटाग्लिप्टिन और मेटफॉर्मिन लेबल, दवाओं के इंटरैक्शन)

These medications include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (सैक्साग्लिप्टिन और मेटफॉर्मिन लेबल, दवाओं के इंटरैक्शन)

Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor). (सोडियम ज़िरकोनियम साइक्लोसिलिकेट लेबल, दवाओं के इंटरैक्शन)

No clinically significant drug interactions have been either observed or are expected when DESCOVY is combined with the following drugs: buprenorphine, itraconazole, ketoconazole, lorazepam, methadone, midazolam, naloxone, norbuprenorphine, norgestimate/ethinyl estradiol, and sertraline. (एमट्रिसिटाबिन और टेनोफोविर लेबल, दवाओं के इंटरैक्शन)

No clinically significant drug interactions have been observed between TDF and the following medications: entecavir, methadone, oral contraceptives, ribavirin, sofosbuvir, or tacrolimus in studies conducted in healthy subjects. (एमट्रिसिटाबिन, रिल्पिविरिन और टेनोफोविर लेबल, दवाओं के इंटरैक्शन)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (एलोसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

No significant interactions with digoxin, hydrochlorothiazide, hydralazine, sulfinpyrazone, oral contraceptives, tolbutamide, or warfarin have been observed. (एसिब्यूटोलोल लेबल, दवाओं के इंटरैक्शन)

Other Concomitant Drug Therapy Drug-drug interaction studies conducted in healthy subjects between zileuton immediate-release tablets and prednisone and ethinyl estradiol (oral contraceptive), drugs known to be metabolized by the CYP3A4 isoenzyme, have shown no significant interaction. (ज़ाइल्यूटॉन लेबल, दवाओं के इंटरैक्शन)

In a single-blind, parallel-group, 3-week study in 39 healthy female subjects taking oral contraceptives, 40 mg twice daily of zafirlukast had no significant effect on ethinyl estradiol plasma concentrations or contraceptive efficacy. (ज़ाफिरलुकास्ट लेबल, सावधानियां)

Oral Contraceptives : Multiple dose administration of tiagabine (8 mg/day monotherapy) did not alter the pharmacokinetics of oral contraceptives in healthy women of child-bearing age. (टियागाबिन लेबल, दवाओं के इंटरैक्शन)

Combination oral contraceptives Darifenacin (10 mg three times daily) had no effect on the pharmacokinetics of the combination oral contraceptives containing levonorgestrel and ethinyl estradiol [see Clinical Pharmacology (12.3)] . (डैरिफेनासिन लेबल, दवाओं के इंटरैक्शन)

Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides), and theophylline did not affect the pharmacokinetics of dofetilide. (डोफेटिलाइड लेबल, दवाओं के इंटरैक्शन)

…clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: dolutegravir, lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, and midazolam [see Clinical Pharmacology (12.3) ] . (डोराविरिन लेबल, दवाओं के इंटरैक्शन)

Oral Contraceptives In the presence of fesoterodine, there are no clinically significant changes in the plasma concentrations of combined oral contraceptives containing ethinyl estradiol and levonorgestrel [see Clinical Pharmacology (12.3) ] . (फेसोटेरोडिन लेबल, दवाओं के इंटरैक्शन)

No dose adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology… (मोंटेलुकास्ट लेबल, दवाओं के इंटरैक्शन)

Drugs without Clinically Significant Interactions with ISENTRESS In drug interaction studies, raltegravir did not have a clinically meaningful effect on the pharmacokinetics of the following: hormonal contraceptives, methadone, lamivudine, tenofovir, etravirine, darunavir/ritonavir, or boceprevir. (राल्टेग्राविर लेबल, दवाओं के इंटरैक्शन)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (रिज़ाट्रिप्टान लेबल, दवाओं के इंटरैक्शन)

…sofosbuvir is used with the following drugs [see Clinical Pharmacology (12.3) ]: abacavir, atazanavir/ritonavir, cyclosporine, darunavir/ritonavir, dolutegravir, efavirenz, elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide, emtricitabine, lamivudine, methadone, midazolam, oral contraceptives, pravastatin, raltegravir, rilpivirine, tacrolimus, or verapamil. (लेडिपासविर और सोफोसबुविर लेबल, दवाओं के इंटरैक्शन)

…clinically significant drug interactions have been observed with the following drugs [see Clinical Pharmacology (12.3) ]: VOSEVI: cobicistat, darunavir, elvitegravir, emtricitabine, ethinyl estradiol/norgestimate, gemfibrozil, rilpivirine, ritonavir, tenofovir alafenamide, voriconazole Sofosbuvir/velpatasvir: dolutegravir, ketoconazole, raltegravir Sofosbuvir:… (सोफोसबुविर और वेल्पाटासविर लेबल, दवाओं के इंटरैक्शन)